reduction in general has not attracted much attention as a
stereoselective reduction method.4 In the few examples of MPV
reductions with reported high diastereoselectivities, stoichio-
metric amounts of aluminum alkoxides were used.5 Therefore,
MPV reduction has seen very limited applications for diaste-
reoselective reductions in modern synthetic organic chemistry,
and various boron hydrides and aluminum hydrides are usually
the preferred agents. To realize the full potential of the MPV
reduction, it is important to develop catalytic and highly
stereoselectiVe processes. Here, we report such a process for
the syntheses of ephedrine analogues and monoprotected 1,2-
diols.
Highly Diastereoselective Catalytic
Meerwein-Ponndorf-Verley Reductions
Jingjun Yin,* Mark A. Huffman, Karen M. Conrad, and
Joseph D. Armstrong, III
Department of Process Research, Merck Research Laboratories,
P.O. Box 2000, Rahway, New Jersey 07065
Ephedrine and its analogues (4) are widely used as chiral
auxiliaries6 and chiral resolution agents7 and also have important
implications in weight control and treatment of obesity.8 As
shown in Scheme 1,9 4 could be obtained by direct LiAlH4
reduction of 3, whose precursor 2 could be readily prepared
from commercially available enantiopure carbamate-protected
alanine 1 (X ) OH) via activation as an acyl chloride or a
Weinreb amide [X ) Cl or NMe(OMe)].10 PhMe2SiH-TFA
was the most effective condition for the key diastereoselective
reduction of 2 [diastereomeric ratio (d.r.) > 98:2],9b,c but the
relatively high cost of PhMe2SiH and use of TFA as solvent
limited the application of this method on a large scale.
We were interested in developing a practical reduction of
the aminoketone 2-3 and started by screening the commonly
used reducing agents for this reaction (Table 1). The bistrif-
luoromethyl ketone 2a was a good substrate because of its high
reactivity and good compatibility of CF3 groups to various
reducing agents.11
ReceiVed October 10, 2005
Very practical synthesis of ephedrine analogues in high yields
and enantiopurity was realized by a highly diastereoselective
Meerwein-Ponndorf-Verley (MPV) reduction of protected
R-amino aromatic ketones using catalytic aluminum isopro-
poxide. The high anti selectivity resulted from the chelation
of the nitrogen anion to the aluminum. In contrast, high syn
selectivity was obtained with R-alkoxy ketones and other
compounds via Felkin-Ahn control.
The TFA-PhMe2SiH procedure9b,c did give a very high d.r.
(entry 1), but the use of a cheaper silane Et3SiH resulted in
slow and incomplete reactions. Among various borohydrides
(entries 2-10), only NaB(OAc)3H gave a reasonable d.r. of 4.9:1
(entry 9); however, this reaction was sluggish, and attempts to
further optimize it failed. Simple aluminum hydrides such as
LiAlH4 and LiAl(OtBu)3H gave moderate undesired selectivities
The Meerwein-Ponndorf-Verley (MPV) reduction of ke-
tones and aldehydes has been known for 80 years.1 It generally
i
uses inexpensive and environmentally friendly PrOH as a
hydride source and aluminum alkoxides as catalysts, and the
reaction is chemoselective, easy to operate, and readily scalable.2
These apparent practical advantages make the MPV reduction
a particularly attractive green-chemistry approach for reduction
of carbonyl compounds. However, aluminum-mediated MPV
reduction is limited by its requirement of a stoichiometric
amount of the aluminum alkoxide catalyst and sometimes low
yields due to side reactions.2 A number of modified aluminum
catalyst systems have been designed for catalytic MPV reduc-
tions,3 but they either give side reactions due to increased Lewis
acidity3a or require complex ligands3b-d or pyrophoric starting
materials.3e Additionally, although enantioselective aluminum-
catalyzed MPV reduction has met with moderate success,2c MPV
(4) The MPV reduction was generally not considered to give good
diastereoselectivities. See ref 2a.
(5) (a) Lund, H. Ber. 1937, 70B, 1520. (b) Jackman, L. M.; Macbeth,
A. K.; Mills, J. A. J. Chem. Soc. 1949, 2641. (c) Banthorpe, D. V.; Davies,
H. ff. S. J. Chem. Soc. B 1968, 1356. (d) Mueller, H. K.; Schuart, J.;
Baborowski, H. J. Prakt. Chem. 1973, 315, 1045. (e) Hach, V. J. Org.
Chem. 1973, 38, 293. (f) Kuroboshi, M.; Ishihara, T. Bull. Chem. Soc. Jpn.
1990, 63, 1185. (g) Hilpert, H. EP 703209, 1996. (h) Satoh, H.; Yamamoto,
K. EP 934923, 1999. (i) Matsuo, K.; Matsumoto, S.; Inoue, K. WO 9855452,
1998. (j) Brown, J. D.; Cain, R. O.; Kopach, M. E. EP 963972, 1999. (k)
Urban, F. J.; Jasys, V. J. Org. Process Res. DeV. 2004, 8, 169.
(6) Selected examples: (a) Rueck, K. Angew. Chem., Int. Ed. Engl. 1995,
34, 433. (b) Anakabe, E.; Badia, D.; Carrillo, L.; Rodriguez, M.; Vicario,
J. L. Trends Org. Chem. 2001, 9, 29.
(7) Enantiomers, Racemates, and Resolutions; Jacques, J., Collet, A.,
Wilen, S. H., Eds.; Krieger: Malabar, FL,1991.
(1) (a) Meerwein, H.; Schmidt, R. Justus Liebigs Ann. Chem. 1925, 444,
221. (b) Ponndorf, W. Angew. Chem. 1926, 39, 138. (c) Verley, M. Bull.
Soc. Chim. Fr. 1925, 37, 871.
(2) Reviews: (a) Wilds, A. L. Org. React. 1944, 2, 178. (b) de Graauw,
C. F.; Peters, J. A.; van Bekkum, H.; Huskens, J. Synthesis 1994, 1007. (c)
Nishide, K.; Node, M. Chirality 2002, 14, 759.
(3) (a) Kow, R.; Nygren, R.; Rathke, M. W. J. Org. Chem. 1977, 42,
826. (b) Ko, B.-T.; Wu, C.-C.; Lin, C.-C. Organometallics 2000, 19, 1864.
(c) Konishi, K.; Makita, K.; Aida, T.; Inoue, S. J. Chem. Soc., Chem.
Commun. 1988, 643. (d) Ooi, T.; Miura, T.; Maruoka, K. Angew Chem.,
Int. Ed. 1998, 37, 2347. (e) Campbell, E. J.; Zhou, H.; Nguyen, S. T. Org.
Lett. 2001, 3, 2391.
(8) Selected examples: (a) Clapham, J. C. Curr. Drug Targets 2004, 5,
309. (b) Dulloo, A. G. Int. J. Obes. 2002, 26, 590.
(9) (a) Buckley, T. F., III.; Rapoport, H. J. Am. Chem. Soc. 1981, 103,
6157. (b) Fujita, M.; Hiyama, T. J. Am. Chem. Soc. 1984, 106, 4629. (c)
Fujita, M.; Hiyama, T. J. Org. Chem. 1988, 53, 5415.
(10) (a) Skiles, J. W.; Fuchs, V.; Miao, C.; Sorcek, R.; Grozinger, K.
G.; Mauldin, S. C.; Vitous, J.; Mui, P. W.; Jacober, S.; Chow, G.; Matteo,
M.; Skoog, M.; Weldon, S. M.; Possanza, G.; Keirns, J.; Letts, G.; Rosentha,
A. S. J. Med. Chem. 1992, 35, 641. (b) Kano, S.; Yokomatsu, T.; Iwasawa,
H.; Shibuya, S. Tetrahedron Lett. 1987, 28, 6331.
(11) Unlike many other ketones in Table 2, the product isomers 3a/5a
are readily separated by LC for easy analysis during screening.
10.1021/jo052121t CCC: $33.50 © 2006 American Chemical Society
Published on Web 12/16/2005
840
J. Org. Chem. 2006, 71, 840-843